TabletsClinical Overview
Clopidogrel Bisulphate is an oral thienopyridine P2Y12 platelet inhibitor on the WHO Model List of Essential Medicines. It requires hepatic bioactivation by CYP2C19 to form an active thiol metabolite that irreversibly modifies platelet P2Y12 ADP receptors for the entire 7-10 day lifespan of the platelet, preventing ADP-induced platelet activation and fibrinogen binding. Indicated for secondary prevention of atherothrombotic events in patients with recent myocardial infarction, recent ischemic stroke, or established peripheral arterial disease, and as part of DAPT in acute coronary syndromes.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily with a glass of water, with or without meals. Maintain consistent daily timing. Do not discontinue without consulting your cardiologist.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Hematoma, epistaxis, gastrointestinal hemorrhage, bruising, dyspepsia, diarrhea. Rare/Severe: Boxed warning: Diminished antiplatelet effect in CYP2C19 poor metabolizers; major fatal hemorrhage, and thrombotic thrombocytopenic purpura (TTP).
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black box warning: Reduced effectiveness in CYP2C19 poor metabolizers; consider alternative P2Y12 inhibitors (prasugrel, ticagrelor) if indicated. Contraindicated in active pathological bleeding (peptic ulcer, intracranial hemorrhage). Avoid concurrent omeprazole/esomeprazole which inhibit CYP2C19; use pantoprazole instead if gastric protection is needed.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified cardiologist/pharmacist before initiating, altering, or substituting any cardiovascular medication.
Clopidogrel 75mg + Aspirin 75mg Tablets
Clopidogrel and Aspirin is the cornerstone Dual Antiplatelet Therapy (DAPT) on the WHO Model List of Essential Medicines. Aspirin irreversibly acetylates platelet cyclooxygenase-1 (COX-1), blocking thromboxane A2 production, while clopidogrel is an oral thienopyridine prodrug whose active metabolite irreversibly binds to platelet P2Y12 adenosine diphosphate (ADP) receptors, preventing ADP-mediated glycoprotein IIb/IIIa activation. This dual blockade potently inhibits platelet aggregation across complementary pathways. Indicated for acute coronary syndromes (STEMI, NSTEMI, unstable angina) and prevention of subacute stent thrombosis following percutaneous coronary intervention (PCI).
Atorvastatin 10mg + Clopidogrel 75mg Capsules
Statin and Antiplatelet (Aspirin +/- Clopidogrel) cardiovascular polypill formulation. Unites intensive lipid lowering and plaque stabilization (via HMG-CoA reductase inhibition) with antiplatelet thrombus prevention (via irreversible COX-1 inhibition and/or ADP P2Y12 platelet receptor blockade). Indicated for secondary prevention in coronary artery disease, acute coronary syndrome, post-percutaneous coronary intervention (PCI/stenting), and ischemic stroke.
Rosuvastatin 10mg + Clopidogrel 75mg Capsules
Statin and Antiplatelet (Aspirin +/- Clopidogrel) cardiovascular polypill formulation. Unites intensive lipid lowering and plaque stabilization (via HMG-CoA reductase inhibition) with antiplatelet thrombus prevention (via irreversible COX-1 inhibition and/or ADP P2Y12 platelet receptor blockade). Indicated for secondary prevention in coronary artery disease, acute coronary syndrome, post-percutaneous coronary intervention (PCI/stenting), and ischemic stroke.
Atorvastatin 20mg + Clopidogrel 75mg Capsules
Statin and Antiplatelet (Aspirin +/- Clopidogrel) cardiovascular polypill formulation. Unites intensive lipid lowering and plaque stabilization (via HMG-CoA reductase inhibition) with antiplatelet thrombus prevention (via irreversible COX-1 inhibition and/or ADP P2Y12 platelet receptor blockade). Indicated for secondary prevention in coronary artery disease, acute coronary syndrome, post-percutaneous coronary intervention (PCI/stenting), and ischemic stroke.